ForPatients
by Roche

Duchenne Muscular Dystrophy (DMD)

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD)

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03375164 IRB17-00512, 2021-000077-83 SRP-9001-101

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study was an open-label single-dose gene transfer therapy study evaluating the safety of delandistrogene moxeparvovec intravenous (IV) administration in boys with DMD. This study was originally designed to consist of 12 patients across 2 Cohorts. Cohort A would have included participants ages 3 months to 3 years, and Cohort B included participants ages 4 to 7 years old. No participants were enrolled in Cohort A.

Sarepta Therapeutics, Inc.	Phase 1/Phase 2
Sponsor	Phase

NCT03375164 IRB17-00512, 2021-000077-83 SRP-9001-101
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Male	>=3 Months & <= 7 Years	No